SOLICITATION NOTICE
B -- Preparation and Qualification of a pre-cleared, irradiated, anti-CD3-antibody loaded K562 CD64, HLA-A2, 4-IBBL Working Cell Bank
- Notice Date
- 9/9/2010
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100239-CR
- Archive Date
- 10/1/2010
- Point of Contact
- Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
cr214i@nih.gov
(cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Description The National Cancer Institute (NCI), Immunology Section, Pediatric Oncology Branch plans to procure on a sole source basis the Preparation and Qualification of a pre-cleared, irradiated, anti-CD3-antibody loaded K562 CD64, HLA-A2, 4-IBBL Working Cell Bank from the Clinical Cell and Vaccine Production Facility, University of Pennsylvania Abramson Cancer Center, 3451 Walnut Street, Philadelphia, PA 19104-6205. This acquisition will be processed under the procedures for FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 541990 and the business size standard is $7.0 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery Date: Three (3) months after award. The mission of the Immunology Section, Pediatric Oncology Branch, NCI, is to develop effective immune based therapies for childhood cancer. Previous work has demonstrated T cells and NK cells can be efficiently expanded ex vivo using artificial antigen presenting cells (aAPCs) expressing 4-IBBL. The NCI has previously purchased an aAPC master cell bank produced by the Clinical Cell and Vaccine Production Facility at the Abramson Cancer Institute at the University of Pennsylvania which expresses K562 CD64, 4-IBBL and HLA-A2. These cells potently expand NK cell populations and the NCI plans to use it to expand NK cells for use in a clinical trial of adoptive immunotherapy following allogeneic stem cell transplantation. The purpose of this project is to create a GMP grade working cell bank from the above mentioned master cell bank for use in an upcoming NCI clinical trial. The Clinical Cell and Vaccine Production Facility (CVPF) is the only source for the working cell bank since they were the creator of the cell bank and have the intellectual property rights to the bank. The CVPF was previously used to qualify the master cell bank and therefore has already performed the quality control testing on these cell banks; accordingly, they have the unique experience and expertise in the evaluation of this product. Using an alternative vendor would introduce a significant new variable into the analyses which could adversely affect the ability to interpret study results. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received at the NCI Office of Acquisitions on or before 11:00 AM EST on September 15, 2010. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Caren Rasmussen, Contracting Officer at rasmussc@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100239-CR on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100239-CR/listing.html)
- Record
- SN02275995-W 20100911/100910000951-23e48584906fb00e288807ae34937866 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |